|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng L, Wu C, Xi P, et al: The survival
and the long-term trends of patients with gastric cancer in
Shanghai, China. BMC Cancer. 14:3002014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ychou M, Boige V, Pignon JP, et al:
Perioperative chemotherapy compared with surgery alone for
resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD
multicenter phase III trial. J Clin Oncol. 29:1715–1721. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dikken JL, Jansen EP, Cats A, et al:
Impact of the extent of surgery and postoperative chemoradiotherapy
on recurrence patterns in gastric cancer. J Clin Oncol.
28:2430–2436. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yan SM, Tang JJ, Huang CY, et al: Reduced
expression of ZDHHC2 is associated with lymph node metastasis and
poor prognosis in gastric adenocarcinoma. PLoS One. 8:e563662013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Isobe T, Aoyagi K, Koufuji K, et al:
Clinicopathological significance of hypoxia-inducible factor-1
alpha (HIF-1alpha) expression in gastric cancer. Int J Clin Oncol.
18:293–304. 2013. View Article : Google Scholar
|
|
7
|
Lee J and Ou SH: Towards the goal of
personalized medicine in gastric cancer-time to move beyond HER2
inhibition. Part II: Targeting gene mutations and gene
amplifications and the angiogenesis pathway. Discov Med. 16:7–14.
2013.PubMed/NCBI
|
|
8
|
Boku N: HER2-positive gastric cancer.
Gastric Cancer. 17:1–12. 2014. View Article : Google Scholar :
|
|
9
|
Luis M, Tavares A, Carvalho LS, et al:
Personalizing therapies for gastric cancer: molecular mechanisms
and novel targeted therapies. World J Gastroenterol. 19:6383–6397.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He C, Bian XY, Ni XZ, et al: Correlation
of human epidermal growth factor receptor 2 expression with
clinicopathological characteristics and prognosis in gastric
cancer. World J Gastroenterol. 19:2171–2178. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tzachanis D and Boussiotis VA: Tob, a
member of the APRO family, regulates immunological quiescence and
tumor suppression. Cell Cycle. 8:1019–1025. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin S, Zhu Q, Xu Y, et al: The role of the
TOB1 gene in growth suppression of hepatocellular carcinoma. Oncol
Lett. 4:981–987. 2012.PubMed/NCBI
|
|
13
|
O’Malley S, Su H, Zhang T, et al: TOB
suppresses breast cancer tumorigenesis. Int J Cancer.
125:1805–1813. 2009. View Article : Google Scholar
|
|
14
|
Jiao Y, Sun KK, Zhao L, et al: Suppression
of human lung cancer cell proliferation and metastasis in vitro by
the transducer of ErbB-2.1 (TOB1). Acta Pharmacol Sin. 33:250–260.
2012. View Article : Google Scholar
|
|
15
|
Wang XM, Li J, Yan MX, et al: Integrative
analyses identify osteopontin, LAMB3 and ITGB1 as critical
pro-metastatic genes for lung cancer. PLoS One. 8:e557142013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang YX, Zhang XY, Zhang BF, et al: Study
on the clinical significance of Argonaute2 expression in colonic
carcinoma by tissue microarray. Int J Clin Exp Pathol. 6:476–484.
2013.PubMed/NCBI
|
|
17
|
Sun Z, Wang ZN, Zhu Z, et al: Evaluation
of the seventh edition of American Joint Committee on Cancer TNM
staging system for gastric cancer: results from a chinese
monoinstitutional study. Ann Surg Oncol. 19:1918–1927. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoshida Y, Nakamura T, Komoda M, et al:
Mice lacking a transcriptional corepressor Tob are predisposed to
cancer. Genes Dev. 17:1201–1206. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kundu J, Wahab SM, Kundu JK, et al: Tob1
induces apoptosis and inhibits proliferation, migration and
invasion of gastric cancer cells by activating Smad4 and inhibiting
betacatenin signaling. Int J Oncol. 41:839–848. 2012.PubMed/NCBI
|
|
20
|
Liu F, Cao Q, Liu N, et al: Overexpression
of testes-specific protease 50 (TSP50) predicts poor prognosis in
patients with gastric cancer. Gastroenterol Res Pract.
2014:4982462014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu Z, Wang J, Sun Z, et al: Flotillin2
expression correlates with HER2 levels and poor prognosis in
gastric cancer. PLoS One. 8:e623652013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou S, Xu S, Tao H, et al: CCR7
expression and intratumoral FOXP3+ regulatory T cells are
correlated with overall survival and lymph node metastasis in
gastric cancer. PLoS One. 8:e744302013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Taubert H, Heidenreich C, Holzhausen HJ,
et al: Expression of survivin detected by immunohistochemistry in
the cytoplasm and in the nucleus is associated with prognosis of
leiomyosarcoma and synovial sarcoma patients. BMC Cancer.
10:652010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Q, Zhao ZB, Wang G, et al: High
expression of KIF26B in breast cancer associates with poor
prognosis. PLoS One. 8:e616402013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ezzeddine N, Chang TC, Zhu W, et al: Human
TOB, an antiproliferative transcription factor, is a
poly(A)-binding protein-dependent positive regulator of cytoplasmic
mRNA deadenylation. Mol Cell Biol. 27:7791–7801. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Helms MW, Kemming D, Contag CH, et al:
TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is
highly phosphorylated and indicates poor prognosis in node-negative
breast cancer. Cancer Res. 69:5049–5056. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoneda M, Suzuki T, Nakamura T, et al:
Deficiency of anti-proliferative family protein Ana correlates with
development of lung adenocarcinoma. Cancer Sci. 100:225–232. 2009.
View Article : Google Scholar
|
